- Shares of BridgeBio Pharma ( NASDAQ: BBIO ) are up 11% in premarket trading after reporting positive phase 2 results for infigratinib in children with achondroplasia.
- At the highest dose level (0.128 mg/kg once daily), mean increase in annualized height velocity (AHV) was 1.52 cm/yr over baseline. In this cohort, 64% were responders and average percent change from baseline in AHV was 60%.
- The study, PROPEL 2, enrolled children as young as three years old. Median follow-up was 48.1 weeks. No treatment-related severe adverse events were reported.
- Based on the results, BridgeBio ( BBIO ) has begun dosing (0.25 mg/kg once daily) in another cohort.
- Seeking Alpha's Quant Rating views BridgeBio ( BBIO ) as a hold with high grades from revisions and growth .
For further details see:
BridgeBio up 11% following positive mid-stage results of infigratinib in achondroplasia